Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) Rally 1.23% - Insider Trading Report PDF Print

Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) appreciated by 1.23% during the past week but lost 17.68% on a 4-week basis. The shares have outperformed the S&P 500 by 2.51% in the past week but underperformed the index by 17.72% in the last 4 weeks.

Rockwell Medical, Inc. is up 32.29% in the last 3-month period. Year-to-Date the stock performance stands at 35.89%. The company shares have rallied 25.52% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of $18.9 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $15.83 and the 200 day moving average is recorded at $12.05. S&P 500 has rallied 7.26% during the last 52-weeks. The company has received recommendation from many analysts. 2 analysts have rated the company as a strong buy. 1 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Friday session in red amid volatile trading. The shares closed down 0.28 points or 1.96% at $13.97 with 377,583 shares getting traded. Post opening the session at $14.21, the shares hit an intraday low of $13.7 and an intraday high of $14.25 and the price vacillated in this range throughout the day. The company has a market cap of $702 million and the number of outstanding shares have been calculated to be 50,223,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is $18.8999 and the 52-week low is $8.095. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.


Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.